A Phase 2 interventional study of Apremilast in Psoriasis-Type Psoriasis and Plaque-Type Psoriasis, sponsored by Amgen. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-07.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing apremilast in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. apremilast · Psoriasis.
Among the 44 studies testing apremilast in Psoriasis, this one is the 32nd largest by enrollment, is the only one that started in 2007, is one of 10 in phase 2, and was the 1st registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →5 of the 44 studies testing apremilast in Psoriasis are open now, in 3 countries. Recruiting first, the newest first:
Syeda Sana Zaman · Sites in Pakistan
Ages 18–60 · Healthy volunteers
University of Athens · Sites in Greece
Ages 18–80 · Healthy volunteers
Amgen
Ages 18–60 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
Zarmeen Khawar · Sites in Pakistan
Ages 18–65
By country, each count listing its studies:
apremilast: first FDA approval 2014 (OTEZLA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 31 is below the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 103 across the 44 interventional studies. Of the 34 that completed or were terminated, 26 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 44 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
61 studies in Psoriasis by Amgen: 1 open now, 1 under way, none of them phase 3. Of 60 finished, 35 (58%) have results posted.
Among the 61 studies in Psoriasis by Amgen, this one is the 44th largest by enrollment of the 49 interventional ones that give a count, is one of 2 that started in 2007, is one of 8 in phase 2, and was the 13th registered.
Amgen’s Psoriasis studies by the year they started, since 2000.
1 of the studies testing apremilast in Psoriasis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07908641AmgenComparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or Immediate-release Formulation | 2027-01-10 |
Add it to your calendar (.ics) → With an account.
Among the 44 studies testing apremilast in Psoriasis, from their registry updates:
Among Amgen’s 61 in Psoriasis:
This tab as a report to print or save as PDF → With an account.
The study will test the safety and tolerability of Apremilast twice a day in participants with recalcitrant plaque type psoriasis.
This is a phase 2, multicenter, open-label, study to evaluate the safety, tolerability, pharmacodynamics, pharmacokinetics and efficacy of Apremilast in participants with recalcitrant plaque-type psoriasis.
Approximately 31 participants were enrolled and received 20 mg apremilast orally BID and, in participants who are non-responders after 84 days of apremilast, 30 mg Apremilast over the course of the two study treatment phases. The study consisted of four phases: Screening Phase - up to 35 days, Treatment Phase of 84 days, Extension Phase of 84 days and a Observational Follow-up Phase of 28 days.
During the Treatment Phase, participants received two 20 mg Apremilast capsules each day. Following the Treatment Phase, participants had the option to continue on treatment during the Extension Phase. During the Extension Phase, participants either continued to take two 20 mg or dose escalated to two 30 mg of Apremilast each day. Participants who were considered responders (achieved a Psoriasis Area and Severity Index (PASI-75) at the beginning of the Extension Phase continued on 20 mg twice per day (BID) while the remaining participants received 30 mg capsules BID. The Extension Phase was introduced after some participants had already completed the study; therefore, there were several participants who never had the opportunity to continue into the Extension Phase. All participants were asked to participate in a 4-week post-treatment observational follow-up phase either upon completion of the study or upon discontinuation of study drug for those participants who terminated the study early.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Must understand and voluntarily sign an form
Subjects must fulfill criteria outlined in at least one of the following clinical categories:
Must meet the specified laboratory criteria:
o Must be able to adhere to the study visit schedule and study protocol requirements
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Apremilast 20 mg or 30 mg orally twice per day
Drug: Apremilast
20 mg PO (by mouth) twice per day (BID) for 84 days and then an additional 84 days during the optional treatment extension period. For subjects meeting the dose escalation criteria, dosage during the optional treatment extension period can be increased to 30 mg BID.
Also known as: Otezla, CC-10004
Treatment Emergent Adverse Events (TEAEs) During the Treatment Phase
TEAE = any AE occurring or worsening on or after the first treatment with any study drug. Related = suspected by investigator to be related to study treatment. National Cancer Institute \[NCI\] Common Toxicity Criteria for Adverse Events \[CTCAE\], Version 3.0, grades: 1 = mild, 2 = moderate, 3 = severe, 4 = life threatening, 5 = death. Adverse event (AE) = any noxious, unintended, or untoward medical occurrence occurring at any dose that may appear or worsen in a participant during the course of a study, including new intercurrent illness, worsening concomitant illness, injury, or any concomitant impairment of participant's health, including laboratory test values, regardless of etiology. Serious adverse event (SAE) = any AE which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect; constitutes an important medical event.
Time frame: Week 0 to Week 12
Treatment Emergent Adverse Events (TEAEs) During the Extension Phase
TEAE = any AE occurring or worsening on or after the first treatment with any study drug. Related = suspected by investigator to be related to study treatment. National Cancer Institute \[NCI\] Common Toxicity Criteria for Adverse Events \[CTCAE\], Version 3.0, grades: 1 = mild, 2 = moderate, 3 = severe, 4 = life threatening, 5 = death. Adverse event (AE) = any noxious, unintended, or untoward medical occurrence occurring at any dose that may appear or worsen in a participant during the course of a study, including new intercurrent illness, worsening concomitant illness, injury, or any concomitant impairment of participant's health, including laboratory test values, regardless of etiology. Serious adverse event (SAE) = any AE which: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event.
Time frame: Week 12 to Week 24
Percentage of Participants With at Least a 1 Point Reduction on 0 to 5 Point Scale From Baseline in Static Physician Global Assessment (sPGA) at Week 12
The static Physician's Global Assessment (sPGA) rated the investigator's overall clinical assessment of a participants plaque thickness, erythema, and scaling on a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (majority of plaques have severe thickness, erythema, and scale). To assign a sPGA score, the investigator examined all psoriatic lesions and assigned a severity score ranging from 0 to 5 for thickness, erythema, and scaling. Scores for thickness, erythema, and scaling are summed and the mean of these 3 scores equals the overall sPGA score. Decreases in sPGA correspond to clinical improvement.
Time frame: Baseline and Week 12
Percent Change From Baseline in Psoriasis Area Severity Index (PASI) Score at Week 12
The PASI score was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. These values for each anatomic region are summed to yield the PASI score.
Time frame: Baseline and Week 12
Percentage of Participants Who Achieved a PASI-75 Score at Week 12
PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 12. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant.
Time frame: Baseline to Week 12
Percentage of Participants Who Achieved a PASI-50 Score at Week 12
PASI -50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score at Week 12. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head,trunk, upper limbs, and lower limbs. Degree of involvement on each of the4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant.
Time frame: Baseline to Week 12
Maximal PASI Response Documented for Each Participant During Treatment Phase
PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head,trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) is multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. These values for each anatomic region are summed to yield the PASI score.
Time frame: Baseline to Week 12
Percent Change From Baseline in the Psoriasis Affected Body Surface Area (BSA) Involvement at Week 12
The BSA estimate was based on the palm area of the hand of the participant which equates to 1% of the total body surface area.
Time frame: Baseline to Week 12
Time to Clinically Relevant Response (Time to Achieve PASI-50) During Treatment Phase
Time to clinically relevant response (time to achieve PASI-50) during treatment phase was not analyzed. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head,trunk, upper limbs, and lower limbs. Degree of involvement on each of the4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. These values for each anatomic region are summed to yield the PASI score.
Time to Achieve PASI-75 During Treatment Phase
Time to achieve PASI-75 during treatment phase was not analyzed. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. These values for each anatomic region are summed to yield the PASI score.
Time to Relapse of Psoriasis (50% Loss of Maximal PASI Score Improvement in Participants Who Achieved at Least PASI-50 During the Treatment Phase) During the Observational Follow up Phase
Time to relapse of psoriasis (50% loss of maximal PASI score improvement in participants who achieved at least PASI-50 during the treatment phase) during the observational follow up phase was not analyzed. Time to relapse of psoriasis was defined as a 50% loss of maximal PASI score improvement in participants who achieved at least PASI-50 during the treatment or extension phase. The lesion on each area of the body was assessed for redness, thickness, and scaling.
Time frame: 28-day Observational Follow-up Phase; Days 168 to Day 196.
Percent of Participants With Psoriatic Arthritis Who Achieved an American College of Rheumatology 20% Improvement (ACR-20) Response at Week 12
A participant was a responder if the following 3 criteria for improvement from baseline were met: * ≥ 20% improvement in 78 tender joint count; * ≥ 20% improvement in 76 swollen joint count; and * ≥ 20% improvement in at least 3 of the 5 following parameters: Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); Patient's global assessment of disease activity (measured on a 100 mm VAS); Physician's global assessment of disease activity (measured on a 100 mm VAS); Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); C-Reactive Protein.
Time frame: Baseline to Week 12
Time to Relapse of Psoriatic Arthritis During the Observational Follow-up Phase
A relapse was defined as a 50% loss of maximal American College of Rheumatoid (ACR) Score improvement in participants with psoriatic arthritis who achieved at least an ACR 20 score during the treatment phase. Relapses were only captured prior to the prescription of concomitant psoriatic treatment.
Time frame: Observational follow up phase; Days 168 to Day 196
Area Under the Plasma Concentration Time-curve From 0 to 12 Hours Post Dose (AUC 0-12)
Plasma concentrations of apremilast were determined using validated chiral liquid chromatography-mass spectrometry methods (LC-MS/MS). For Day 1, AUC0-12 was calculated, using linear trapezoidal area method in WinNonlin (linear-linear trapezoidal). For Days 85 and 169/170, the AUC during a dosing interval (12 hours) (AUC0-12), was calculated at steady-state using the partial area function within WinNonlin. .
Time frame: Day 85 Pre-dose, 0.5, 1, 2, 4, 8, and 12 hours after the AM dose
Peak (Maximum) Plasma Concentration of Medication (Cmax)
The maximum observed plasma concentration of apremilast (Cmax); the maximum plasma concentration (Cmax) was obtained directly from the observed concentration-time data on Days 1, 85, and 169/170, respectively.
Time frame: Day 85 Pre-dose, 0.5, 1, 2, 4, 8, and 12 hours after the AM dose
Trough Plasma Concentration (Cmin)
The trough observed plasma concentration of apremilast (Cmin) was determined directly from the observed pre-AM dose concentration on Day 85.
Time frame: Day 85 Pre-dose
Time to Maximum Plasma Concentration (Tmax) During the Treatment Phase
The time to reach Cmax (Tmax) was obtained directly from the observed concentration-time data on Day 85. Actual times utilized were used for reporting Tmax values.
Time frame: Day 85 Pre-dose, 0.5, 1, 2, 4, 8, and 12 hours after the AM dose
Terminal Phase Elimination Half Life of Apremilast (t½)
Terminal phase elimination half-life (t1/2) was calculated as follows: t1/2 = 0.693/λz. The terminal elimination rate constant (λZ) was estimated by linear regression of the log-transformed concentration-time data.
Time frame: Day 85 Pre-dose, 0.5, 1, 2, 4, 8, and 12 hours after the AM dose
Apparent Total Clearance of Apremilast From Plasma After Extravascular Administration (CLz/F) During the Treatment Phase
The apparent total clearance of apremilast from plasma after extravascular administration (CLz/F); for Day 1, apparent clearance of drug from plasma (CL/F) was not calculated. For Day 85, Apparent clearance of drug from plasma after extravascular administration (CL/F) was calculated as follows: CL/F= Dose/AUC\^12 where τ=12.
Time frame: Day 85 Pre-dose, 0.5, 1, 2, 4, 8, and 12 hours after the AM dose
Apparent Total Volume of Distribution During the Terminal Phase After Extravascular Administration (Vz/F) During the Treatment Phase
Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F) (for Days 1, 85, and 169/170) 1. For Day 1, Vz/F was not calculated. 2. For Days 85 and 169/170, apparent volume of distribution of drug (V/z) based on the terminal phase was calculated as follows: Vz/F=Dose/(λ\*AUC\^12)
Time frame: Day 85
Accumulation Index (R)
Accumulation represents the relationship between the dosing interval and the rate of elimination for the drug.
Time frame: Day 85 Pre-dose, 0.5, 1, 2, 4, 8, and 12 hours after the AM dose
Mean Residence Time (MRT) During the Treatment Phase
Mean Residence Time (MRT) is defined as the mean duration of time the drug spends in the body. The average concentration at steady state (Cavg) (for Day 85 was calculated as follows: Cavg = (Day 85 AUC0-12)/(12).
Time frame: Day 85 Pre-dose, 0.5, 1, 2, 4, 8, and 12 hours after the AM dose
Change From Baseline in Peripheral Blood T Cell, B Cell, and NK Cell Subsets at Week 12
T cells or T lymphocytes, a type of white blood cell, play a role in cell-mediated immunity. T cells are distinguished from other lymphocytes by the presence of a T-cell receptor (TCR) on the cell surface and mature in the thymus. B cells, a type of lymphocyte in the humoral immunity of the adaptive immune system can be distinguished by the presence of a protein on the B cells outer surface called a B cell receptor (BCR). This receptor protein allows a B cell to bind to a specific antigen and make antibodies against antigens \[(antigen-presenting cells APCs)\], and to develop into memory B cells after activation by antigen interaction. Natural Killer Cells (NK) are a type of cytotoxic lymphocyte critical to the innate immune system. Their role is analogous to that of cytotoxic T cells in the vertebrate adaptive immune response. They constitute the third kind of cells differentiated from the common lymphoid progenitor generating B and T lymphocytes and mature in the bone marrow.
Time frame: Baseline and Week 12
Percent Change From Baseline of CD3 in the Dermis of the Psoriatic Skin Biopsy at Week 12
The aim of the study was to measure the pharmacodynamic effects of apremilast in participants with plaque psoriasis in skin affected by psoriasis, immune cells enter the skin through blood vessels and cause the epidermis to grow very rapidly and to stop shedding properly. This causes thickening of the skin as well as the scaly build up composed of dead skin cells seen on areas affected by psoriasis.
Time frame: Baseline and Week 12
Percent Change From Baseline of CD3 in the Epidermis of the Psoriatic Skin Biopsy at Week 12
The aim of the study was to measure the pharmacodynamic effects of apremilast in participants with plaque psoriasis in skin affected by psoriasis, immune cells enter the skin through blood vessels and cause the epidermis to grow very rapidly and to stop shedding properly. This causes thickening of the skin as well as the scaly build up composed of dead skin cells seen on areas affected by psoriasis.
Time frame: Baseline and Week 12
Percent Change From Baseline of CD 11c in the Dermis of the Psoriatic Skin Biopsy at Week 12
The aim of the study was to measure the pharmacodynamic effects of apremilast in participants with plaque psoriasis in skin affected by psoriasis, immune cells enter the skin through blood vessels and cause the epidermis to grow very rapidly and to stop shedding properly. This causes thickening of the skin as well as the scaly build up composed of dead skin cells seen on areas affected by psoriasis.
Time frame: Baseline and Week 12
Percent Change From Baseline of CD11c in the Epidermis of the Psoriatic Skin Biopsy at Week 12
The aim of the study was to measure the pharmacodynamic effects of apremilast in participants with plaque psoriasis in skin affected by psoriasis, immune cells enter the skin through blood vessels and cause the epidermis to grow very rapidly and to stop shedding properly. This causes thickening of the skin as well as the scaly build up composed of dead skin cells seen on areas affected by psoriasis.
Time frame: Baseline and Week 12
Percent Change From Baseline of CD56 in the Dermis of the Psoriatic Skin Biopsy at Week 12
The aim of the study was to measure the pharmacodynamic effects of apremilast in participants with plaque psoriasis in skin affected by psoriasis, immune cells enter the skin through blood vessels and cause the epidermis to grow very rapidly and to stop shedding properly. This causes thickening of the skin as well as the scaly build up composed of dead skin cells seen on areas affected by psoriasis.
Time frame: Baseline and Week 12
Percent Change From Baseline of CD56 in the Epidermis of the Psoriatic Skin Biopsy at Week 12
The aim of the study was to measure the pharmacodynamic effects of apremilast in participants with plaque psoriasis in skin affected by psoriasis, immune cells enter the skin through blood vessels and cause the epidermis to grow very rapidly and to stop shedding properly. This causes thickening of the skin as well as the scaly build up composed of dead skin cells seen on areas affected by psoriasis.
Time frame: Baseline and Week 12
Percent Change From Baseline of Langerin in the Dermis of Psoriatic Skin Biopsy at Week 12
The aim of the study was to measure the pharmacodynamic effects of apremilast in participants with plaque psoriasis in skin affected by psoriasis, immune cells enter the skin through blood vessels and cause the epidermis to grow very rapidly and to stop shedding properly. This causes thickening of the skin as well as the scaly build up composed of dead skin cells seen on areas affected by psoriasis.
Time frame: Baseline and Week 12
Percent Change From Baseline of Langerin in the Epidermis of the Psoriatic Skin Biopsy at Week 12
The aim of the study was to measure the pharmacodynamic effects of apremilast in participants with plaque psoriasis in skin affected by psoriasis, immune cells enter the skin through blood vessels and cause the epidermis to grow very rapidly and to stop shedding properly. This causes thickening of the skin as well as the scaly build up composed of dead skin cells seen on areas affected by psoriasis.
Time frame: Baseline and Week 12
Percent Change From Baseline of Epidermal Thickness in the Psoriatic Skin Biopsy at Week 12
The aim of the study was to measure the pharmacodynamic effects of apremilast in participants with plaque psoriasis in skin affected by psoriasis, immune cells enter the skin through blood vessels and cause the epidermis to grow very rapidly and to stop shedding properly. This causes thickening of the skin as well as the scaly build up composed of dead skin cells seen on areas affected by psoriasis.
Time frame: Baseline and Week 12
Percent Change From Baseline in the Inducible Nitric Oxide (iNOS) Inflammatory Marker in Psoriatic Skin Biopsies
Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.
Time frame: Baseline and Week 12
Percent Change From Baseline in the Interleukin (IL) IL-22 Inflammatory Marker in Psoriatic Skin Biopsies
Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.
Time frame: Baseline and Week 12
Percent Change From Baseline in the p40 Inflammatory Marker in Psoriatic Skin Biopsies
Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.
Time frame: Baseline and Week 12
Percent Change From Baseline in the Defensin Beta 4 (DEFB4) Inflammatory Marker in Psoriatic Skin Biopsies
Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) i being measured.
Time frame: Baseline and Week 12
Percent Change From Baseline in the keratin16 (K16) Inflammatory Marker in Psoriatic Skin Biopsies
Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.
Time frame: Baseline and Week 12
Percent Change From Baseline in the pluripotent19 (P19) Inflammatory Marker in Psoriatic Skin Biopsies
Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.
Time frame: Baseline and Week 12
Percent Change From Baseline in the IL8 Inflammatory Marker in Psoriatic Skin Biopsies
Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.
Time frame: Baseline and Week 12
Percent Change From Baseline in the MX1 (Gene That Encodes the Interferon-induced p78 Protein) Inflammatory Marker in Psoriatic Skin Biopsies
Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.
Time frame: Baseline and Week 12
Percent Change From Baseline in the IL17A Inflammatory Marker in Psoriatic Skin Biopsies
Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.
Time frame: Baseline and Week 12
Percent Change From Baseline in the Tumor Necrosing Factor (TNF) Alpha Inflammatory Marker in Psoriatic Skin Biopsies
Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.
Time frame: Week 0 to Week 12
Percent Change From Baseline in the Interferon (INF) Gamma Inflammatory Marker in Psoriatic Skin Biopsies
Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.
Time frame: Baseline and Week 12
Percent Change From Baseline in the IL10 Inflammatory Marker in Psoriatic Skin Biopsies
Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.
Time frame: Baseline and Week 12
Percent Change From Baseline in the Chemokine Ligand (CXCL9) Inflammatory Marker in Psoriatic Skin Biopsies
Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.
Time frame: Baseline and Week 12
Percent Change From Baseline in the IL2 Inflammatory Marker in Psoriatic Skin Biopsies
Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.
Time frame: Baseline and Week 12
Percent Change From Baseline in the Dendritic Cell (CD83) Inflammatory Marker in Psoriatic Skin Biopsies
Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.
Time frame: Baseline and Week 12
Change From Baseline in the Dermatology Life Quality Index (DLQI) at Week 12
DLQI was the dermatology-specific quality of life (QOL) measure used for the psoriatic population. The DLQI was a validated, self-administered, 10-item questionnaire that measures the impact of skin disease on a participants QoL, based on recall over the past week. Domains include symptoms, feelings, daily activities, leisure, work, personal relationships, and treatment. Possible responses for each of the 10 items are: not at all, a little, a lot, and very much. Each question is rated on a scale of 0 to 3 with a total range of 0 to 30. Higher scores indicate greater impact of disease on QOL
Time frame: Baseline to Week 12
Change From Baseline in the Medical Outcome Study Short Form 36-item Health Survey (SF-36) Scores, Mental and Physical Components to Week 12
The SF-36 was a self-administered instrument consisting of 8 multi-item scales that assess 8 health domains: 1) limitations in physical activities because of health problems; 2) limitations in social activities because of physical or emotional problems; 3) limitations in usual role activities because of physical health problems; 4) bodily pain; 5) general mental health (psychological distress and well-being); 6) limitations in usual role activities because of emotional problems; 7) vitality (energy and fatigue); and 8) general health perceptions. A higher score post-baseline is indicative of improvement in the disease state. The summary physical health score included physical functioning, role-physical, bodily pain and general health. The summary mental health score included: vitality, social functioning, role-emotional and mental health. The resulting score for each subscale is then standardized, to obtain values ranging from 0 to 100, with higher values indicating a better QOL.
Time frame: Baseline to Week 12
Area Under the Plasma Concentration Time-curve From 0 to 12 Hours Post Dose (AUC 0-12) During the Extension Phase
Plasma concentrations of apremilast were determined using validated chiral liquid chromatography-mass spectrometry methods (LC-MS/MS).
Time frame: Day 169 pre-dose, 0.5, 1, 2, 4, 8 12, 24 and 36 hours after AM dose
Peak (Maximum) Plasma Concentration of Apremilast (Cmax) During the Extension Phase
The maximum observed plasma concentration of CC-10004 (Cmax); the maximum plasma concentration (Cmax) was obtained directly from the observed concentration-time data on Days 169/170.
Time frame: Day 169 pre-dose, 0.5, 1, 2, 4, 8 12, 24 and 36 hours after AM dose
Time to Maximum Plasma Concentration (Tmax) During the Extension Phase
The time to reach Cmax (Tmax) was obtained directly from the observed concentration-time data on Day 169/170. Actual times utilized were used for reporting Tmax values.
Time frame: Day 169 pre-dose, 0.5, 1, 2, 4, 8 12, 24 and 36 hours after AM dose
Terminal Phase Elimination Half Life of Apremilast (t½) During the Extension Phase
Terminal phase elimination half-life (t1/2) was calculated as follows: t1/2 = 0.693/λz. The terminal elimination rate constant (λZ) was estimated by linear regression of the log-transformed concentration-time data.
Time frame: Day 169 pre-dose, 0.5, 1, 2, 4, 8 12, 24 and 36 hours after AM dose
Apparent Total Clearance of Apremilast From Plasma After Extravascular Administration (CL/F) During the Extension Phase
For 169/170, apparent clearance of drug from plasma after extravascular administration (CL/F) was calculated as follows: CL/F= Dose/AUC12
Time frame: Day 169 pre-dose, 0.5, 1, 2, 4, 8 12, 24 and 36 hours after AM dose
Apparent Total Volume of Distribution During the Terminal Phase After Extravascular Administration (Vz/F) During the Extension Phase
For Days 169/170, apparent volume of distribution of drug (V/z) based on the terminal phase was calculated as follows: Vz/F=Dose/(λ\*AUC12) where λ = the terminal elimination rate constant
Time frame: Day 169 pre-dose, 0.5, 1, 2, 4, 8 12, 24 and 36 hours after AM dose
Accumulation Index During the Extension Phase
Accumulation represents the relationship between the dosing interval and the rate of elimination for the drug.
Time frame: Day 169 pre-dose, 0.5, 1, 2, 4, 8 12, 24 and 36 hours after AM dose
Mean Residence Time (MRT) During the Extension Phase
Mean Residence Time (MRT) is defined as the mean duration of time the drug spends in the body. The average concentration at steady state (Cavg) (for Days169/170) was calculated as follows: Cavg = (Day 169/170)/(12)
Time frame: Day 169 pre-dose, 0.5, 1, 2, 4, 8 12, 24 and 36 hours after AM dose
Participants must have had a diagnosis of plaque-type psoriasis for at least 6 months and had an insufficient response, were unresponsive, intolerant of, or had medical contraindications to standard systemic therapy or biological treatment for plaque-type psoriasis. The study was conducted at 4 sites in the U.S. from 20 August 2007 to 12 May 2009.
| Milestone | Apremilast 20mg | Apremilast 20mg/20mg | Apremilast 20mg/30mg |
|---|---|---|---|
| Started | 31 | 0 | 0 |
| Received apremilast | 30 | 0 | 0 |
| Completed | 19 | 0 | 0 |
| Not completed | 12 | 0 | 0 |
| Withdrew: Adverse event | 2 | 0 | 0 |
| Withdrew: Intolerability to study drug | 2 | 0 | 0 |
| Withdrew: Lack of efficacy | 3 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 |
| Milestone | Apremilast 20mg | Apremilast 20mg/20mg | Apremilast 20mg/30mg |
|---|---|---|---|
| Started | 0 | 4 | 7 |
| Completed | 0 | 4 | 4 |
| Not completed | 0 | 0 | 3 |
| Withdrew: Withdrawal by subject | 0 | 0 | 2 |
| Withdrew: Death | 0 | 0 | 1 |
| Milestone | Apremilast 20mg | Apremilast 20mg/20mg | Apremilast 20mg/30mg |
|---|---|---|---|
| Started | 14 | 4 | 4 |
| Completed | 14 | 4 | 4 |
| Not completed | 0 | 0 | 0 |
TEAE = any AE occurring or worsening on or after the first treatment with any study drug. Related = suspected by investigator to be related to study treatment. National Cancer Institute \[NCI\] Common Toxicity Criteria for Adverse Events \[CTCAE\], Version 3.0, grades: 1 = mild, 2 = moderate, 3 = severe, 4 = life threatening, 5 = death. Adverse event (AE) = any noxious, unintended, or untoward medical occurrence occurring at any dose that may appear or worsen in a participant during the course of a study, including new intercurrent illness, worsening concomitant illness, injury, or any concomitant impairment of participant's health, including laboratory test values, regardless of etiology. Serious adverse event (SAE) = any AE which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect; constitutes an important medical event.
| participants | Apremilast 20 mg |
|---|---|
| ≥ 1 AE | 25 |
| ≥ 1 AE with a suspected relationship to study drug | 13 |
| ≥ 1 severe AE | 3 |
| ≥ 1Severe AE suspected to be related to study drug | 1 |
| ≥ 1 SAE | 0 |
| ≥ AE leading to study drug discontinuation | 4 |
| >=1 treatment-related AE drug discontinued | 2 |
The static Physician's Global Assessment (sPGA) rated the investigator's overall clinical assessment of a participants plaque thickness, erythema, and scaling on a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (majority of plaques have severe thickness, erythema, and scale). To assign a sPGA score, the investigator examined all psoriatic lesions and assigned a severity score ranging from 0 to 5 for thickness, erythema, and scaling. Scores for thickness, erythema, and scaling are summed and the mean of these 3 scores equals the overall sPGA score. Decreases in sPGA correspond to clinical improvement.
| percentage of participants | Apremilast 20 mg PO BID (Treatment Phase) |
|---|---|
| Percentage of Participants With at Least a 1 Point Reduction on 0 to 5 Point Scale From Baseline in Static Physician Global Assessment (sPGA) at Week 12 | 66.7 (47.2 to 82.7) |
The PASI score was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. These values for each anatomic region are summed to yield the PASI score.
| percent change | Apremilast 20 mg |
|---|---|
| Percent Change From Baseline in Psoriasis Area Severity Index (PASI) Score at Week 12 | -59.0 ± 31.59 |
PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 12. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant.
| percentage of participants | Apremilast 20 mg |
|---|---|
| Percentage of Participants Who Achieved a PASI-75 Score at Week 12 | 30.00 (14.7 to 49.4) |
PASI -50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score at Week 12. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head,trunk, upper limbs, and lower limbs. Degree of involvement on each of the4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant.
| percentage of participants | Apremilast 20 mg |
|---|---|
| Percentage of Participants Who Achieved a PASI-50 Score at Week 12 | 46.7 (28.3 to 65.7) |
PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head,trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) is multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. These values for each anatomic region are summed to yield the PASI score.
No measurements were reported for this outcome.
The BSA estimate was based on the palm area of the hand of the participant which equates to 1% of the total body surface area.
| Percent change in BSA | Apremilast 20 mg |
|---|---|
| Percent Change From Baseline in the Psoriasis Affected Body Surface Area (BSA) Involvement at Week 12 | -53.0 ± 35.50 |
Time to clinically relevant response (time to achieve PASI-50) during treatment phase was not analyzed. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head,trunk, upper limbs, and lower limbs. Degree of involvement on each of the4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. These values for each anatomic region are summed to yield the PASI score.
No measurements were reported for this outcome.
Time to achieve PASI-75 during treatment phase was not analyzed. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. These values for each anatomic region are summed to yield the PASI score.
No measurements were reported for this outcome.
Time to relapse of psoriasis (50% loss of maximal PASI score improvement in participants who achieved at least PASI-50 during the treatment phase) during the observational follow up phase was not analyzed. Time to relapse of psoriasis was defined as a 50% loss of maximal PASI score improvement in participants who achieved at least PASI-50 during the treatment or extension phase. The lesion on each area of the body was assessed for redness, thickness, and scaling.
No measurements were reported for this outcome.
A participant was a responder if the following 3 criteria for improvement from baseline were met: * ≥ 20% improvement in 78 tender joint count; * ≥ 20% improvement in 76 swollen joint count; and * ≥ 20% improvement in at least 3 of the 5 following parameters: Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); Patient's global assessment of disease activity (measured on a 100 mm VAS); Physician's global assessment of disease activity (measured on a 100 mm VAS); Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); C-Reactive Protein.
| percentage of participants | Apremilast 20 mg PO BID (Treatment Phase) |
|---|---|
| Percent of Participants With Psoriatic Arthritis Who Achieved an American College of Rheumatology 20% Improvement (ACR-20) Response at Week 12 | 25.0 |
A relapse was defined as a 50% loss of maximal American College of Rheumatoid (ACR) Score improvement in participants with psoriatic arthritis who achieved at least an ACR 20 score during the treatment phase. Relapses were only captured prior to the prescription of concomitant psoriatic treatment.
No measurements were reported for this outcome.
Plasma concentrations of apremilast were determined using validated chiral liquid chromatography-mass spectrometry methods (LC-MS/MS). For Day 1, AUC0-12 was calculated, using linear trapezoidal area method in WinNonlin (linear-linear trapezoidal). For Days 85 and 169/170, the AUC during a dosing interval (12 hours) (AUC0-12), was calculated at steady-state using the partial area function within WinNonlin. .
| ng*hr/mL | Apremilast 20mg |
|---|---|
| Area Under the Plasma Concentration Time-curve From 0 to 12 Hours Post Dose (AUC 0-12) | 2424.48 ± 46.87 |
The maximum observed plasma concentration of apremilast (Cmax); the maximum plasma concentration (Cmax) was obtained directly from the observed concentration-time data on Days 1, 85, and 169/170, respectively.
| ng/mL | Apremilast 20mg |
|---|---|
| Peak (Maximum) Plasma Concentration of Medication (Cmax) | 364.85 ± 38.25 |
The trough observed plasma concentration of apremilast (Cmin) was determined directly from the observed pre-AM dose concentration on Day 85.
| ng/mL | Apremilast 20mg |
|---|---|
| Trough Plasma Concentration (Cmin) | 101.36 ± 71.6 |
The time to reach Cmax (Tmax) was obtained directly from the observed concentration-time data on Day 85. Actual times utilized were used for reporting Tmax values.
| hours | Apremilast 20mg |
|---|---|
| Time to Maximum Plasma Concentration (Tmax) During the Treatment Phase | 2.00 (1.00 to 4.03) |
Terminal phase elimination half-life (t1/2) was calculated as follows: t1/2 = 0.693/λz. The terminal elimination rate constant (λZ) was estimated by linear regression of the log-transformed concentration-time data.
| Liters | Apremilast 20mg |
|---|---|
| Terminal Phase Elimination Half Life of Apremilast (t½) | 7.832 ± 26.031 |
The apparent total clearance of apremilast from plasma after extravascular administration (CLz/F); for Day 1, apparent clearance of drug from plasma (CL/F) was not calculated. For Day 85, Apparent clearance of drug from plasma after extravascular administration (CL/F) was calculated as follows: CL/F= Dose/AUC\^12 where τ=12.
| mL/hour | Apremilast 20mg |
|---|---|
| Apparent Total Clearance of Apremilast From Plasma After Extravascular Administration (CLz/F) During the Treatment Phase | 8249.19 ± 46.87 |
Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F) (for Days 1, 85, and 169/170) 1. For Day 1, Vz/F was not calculated. 2. For Days 85 and 169/170, apparent volume of distribution of drug (V/z) based on the terminal phase was calculated as follows: Vz/F=Dose/(λ\*AUC\^12)
| mL | Apremilast 20mg |
|---|---|
| Apparent Total Volume of Distribution During the Terminal Phase After Extravascular Administration (Vz/F) During the Treatment Phase | 107616.08 ± 47.03 |
Accumulation represents the relationship between the dosing interval and the rate of elimination for the drug.
| ratio | Apremilast 20mg |
|---|---|
| Accumulation Index (R) | 1.68 ± 53.17 |
Mean Residence Time (MRT) is defined as the mean duration of time the drug spends in the body. The average concentration at steady state (Cavg) (for Day 85 was calculated as follows: Cavg = (Day 85 AUC0-12)/(12).
| hours | Apremilast 20mg PO BID |
|---|---|
| Mean Residence Time (MRT) During the Treatment Phase | 202.04 ± 46.87 |
T cells or T lymphocytes, a type of white blood cell, play a role in cell-mediated immunity. T cells are distinguished from other lymphocytes by the presence of a T-cell receptor (TCR) on the cell surface and mature in the thymus. B cells, a type of lymphocyte in the humoral immunity of the adaptive immune system can be distinguished by the presence of a protein on the B cells outer surface called a B cell receptor (BCR). This receptor protein allows a B cell to bind to a specific antigen and make antibodies against antigens \[(antigen-presenting cells APCs)\], and to develop into memory B cells after activation by antigen interaction. Natural Killer Cells (NK) are a type of cytotoxic lymphocyte critical to the innate immune system. Their role is analogous to that of cytotoxic T cells in the vertebrate adaptive immune response. They constitute the third kind of cells differentiated from the common lymphoid progenitor generating B and T lymphocytes and mature in the bone marrow.
| percentage of lymphocytes | Apremilast 20 mg PO BID (Treatment Phase) |
|---|---|
| CD 16 + CD 56 (NK cells) | -0.7 ± 3.05 |
| CD 19 (B-cells) | -0.5 ± 2.63 |
| CD 3 (T-cells) | 0.6 ± 2.63 |
The aim of the study was to measure the pharmacodynamic effects of apremilast in participants with plaque psoriasis in skin affected by psoriasis, immune cells enter the skin through blood vessels and cause the epidermis to grow very rapidly and to stop shedding properly. This causes thickening of the skin as well as the scaly build up composed of dead skin cells seen on areas affected by psoriasis.
| percent change | Apremilast 20 mg PO BID (Treatment Phase) |
|---|---|
| Percent Change From Baseline of CD3 in the Dermis of the Psoriatic Skin Biopsy at Week 12 | -62.0 (-84.3 to 290.9) |
The aim of the study was to measure the pharmacodynamic effects of apremilast in participants with plaque psoriasis in skin affected by psoriasis, immune cells enter the skin through blood vessels and cause the epidermis to grow very rapidly and to stop shedding properly. This causes thickening of the skin as well as the scaly build up composed of dead skin cells seen on areas affected by psoriasis.
| percent change | Apremilast 20 mg PO BID (Treatment Phase) |
|---|---|
| Percent Change From Baseline of CD3 in the Epidermis of the Psoriatic Skin Biopsy at Week 12 | -47.4 (-100.0 to 159.5) |
The aim of the study was to measure the pharmacodynamic effects of apremilast in participants with plaque psoriasis in skin affected by psoriasis, immune cells enter the skin through blood vessels and cause the epidermis to grow very rapidly and to stop shedding properly. This causes thickening of the skin as well as the scaly build up composed of dead skin cells seen on areas affected by psoriasis.
| percent change | Apremilast 20 mg PO BID (Treatment Phase) |
|---|---|
| Percent Change From Baseline of CD 11c in the Dermis of the Psoriatic Skin Biopsy at Week 12 | -54.6 (-88.8 to 284) |
The aim of the study was to measure the pharmacodynamic effects of apremilast in participants with plaque psoriasis in skin affected by psoriasis, immune cells enter the skin through blood vessels and cause the epidermis to grow very rapidly and to stop shedding properly. This causes thickening of the skin as well as the scaly build up composed of dead skin cells seen on areas affected by psoriasis.
| percent change | Apremilast 20 mg PO BID (Treatment Phase) |
|---|---|
| Percent Change From Baseline of CD11c in the Epidermis of the Psoriatic Skin Biopsy at Week 12 | -88.6 (-100.0 to 46.3) |
The aim of the study was to measure the pharmacodynamic effects of apremilast in participants with plaque psoriasis in skin affected by psoriasis, immune cells enter the skin through blood vessels and cause the epidermis to grow very rapidly and to stop shedding properly. This causes thickening of the skin as well as the scaly build up composed of dead skin cells seen on areas affected by psoriasis.
| percent change | Apremilast 20 mg PO BID (Treatment Phase) |
|---|---|
| Percent Change From Baseline of CD56 in the Dermis of the Psoriatic Skin Biopsy at Week 12 | -12.5 (-68.9 to 57.1) |
The aim of the study was to measure the pharmacodynamic effects of apremilast in participants with plaque psoriasis in skin affected by psoriasis, immune cells enter the skin through blood vessels and cause the epidermis to grow very rapidly and to stop shedding properly. This causes thickening of the skin as well as the scaly build up composed of dead skin cells seen on areas affected by psoriasis.
| percent change | Apremilast 20 mg PO BID (Treatment Phase) |
|---|---|
| Percent Change From Baseline of CD56 in the Epidermis of the Psoriatic Skin Biopsy at Week 12 | -73.3 (-100.0 to 311.1) |
The aim of the study was to measure the pharmacodynamic effects of apremilast in participants with plaque psoriasis in skin affected by psoriasis, immune cells enter the skin through blood vessels and cause the epidermis to grow very rapidly and to stop shedding properly. This causes thickening of the skin as well as the scaly build up composed of dead skin cells seen on areas affected by psoriasis.
| percent change | Apremilast 20 mg PO BID (Treatment Phase) |
|---|---|
| Percent Change From Baseline of Langerin in the Dermis of Psoriatic Skin Biopsy at Week 12 | -57.9 (-100.0 to 178.3) |
The aim of the study was to measure the pharmacodynamic effects of apremilast in participants with plaque psoriasis in skin affected by psoriasis, immune cells enter the skin through blood vessels and cause the epidermis to grow very rapidly and to stop shedding properly. This causes thickening of the skin as well as the scaly build up composed of dead skin cells seen on areas affected by psoriasis.
| percent change | Apremilast 20 mg PO BID (Treatment Phase) |
|---|---|
| Percent Change From Baseline of Langerin in the Epidermis of the Psoriatic Skin Biopsy at Week 12 | 17.1 (-78.7 to 300.0) |
The aim of the study was to measure the pharmacodynamic effects of apremilast in participants with plaque psoriasis in skin affected by psoriasis, immune cells enter the skin through blood vessels and cause the epidermis to grow very rapidly and to stop shedding properly. This causes thickening of the skin as well as the scaly build up composed of dead skin cells seen on areas affected by psoriasis.
| percent change | Apremilast 20 mg PO BID (Treatment Phase) |
|---|---|
| Percent Change From Baseline of Epidermal Thickness in the Psoriatic Skin Biopsy at Week 12 | -34.3 (-65.4 to 42.2) |
Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.
| percent change | Apremilast 20 mg PO BID (Treatment Phase) |
|---|---|
| Percent Change From Baseline in the Inducible Nitric Oxide (iNOS) Inflammatory Marker in Psoriatic Skin Biopsies | -100.0 (-100.0 to 55.9) |
Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.
| percent change | Apremilast 20 mg PO BID (Treatment Phase) |
|---|---|
| Percent Change From Baseline in the Interleukin (IL) IL-22 Inflammatory Marker in Psoriatic Skin Biopsies | -100.0 (-100.0 to -44.5) |
Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.
| percent change | Apremilast 20 mg PO BID (Treatment Phase) |
|---|---|
| Percent Change From Baseline in the p40 Inflammatory Marker in Psoriatic Skin Biopsies | -86.7 (-100.0 to 51.7) |
TEAE = any AE occurring or worsening on or after the first treatment with any study drug. Related = suspected by investigator to be related to study treatment. National Cancer Institute \[NCI\] Common Toxicity Criteria for Adverse Events \[CTCAE\], Version 3.0, grades: 1 = mild, 2 = moderate, 3 = severe, 4 = life threatening, 5 = death. Adverse event (AE) = any noxious, unintended, or untoward medical occurrence occurring at any dose that may appear or worsen in a participant during the course of a study, including new intercurrent illness, worsening concomitant illness, injury, or any concomitant impairment of participant's health, including laboratory test values, regardless of etiology. Serious adverse event (SAE) = any AE which: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event.
| participants | Apremilast 20mg/20mg (Extension Phase) | Apremilast 20mg/30mg (Extension Phase) |
|---|---|---|
| ≥ 1 AE | 4 | 5 |
| ≥ 1 AE with a suspected relationship to study drug | 0 | 2 |
| ≥ 1 severe AE | 1 | 1 |
| ≥ 1 SAE | 0 | 1 |
Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) i being measured.
| percent change | Apremilast 20 mg PO BID (Treatment Phase) |
|---|---|
| Percent Change From Baseline in the Defensin Beta 4 (DEFB4) Inflammatory Marker in Psoriatic Skin Biopsies | -82.3 (-100.0 to 14.5) |
Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.
| percent change | Apremilast 20 mg PO BID (Treatment Phase) |
|---|---|
| Percent Change From Baseline in the keratin16 (K16) Inflammatory Marker in Psoriatic Skin Biopsies | -78.6 (-99.9 to 217.7) |
Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.
| percent change | Apremilast 20 mg PO BID (Treatment Phase) |
|---|---|
| Percent Change From Baseline in the pluripotent19 (P19) Inflammatory Marker in Psoriatic Skin Biopsies | -68.3 (-100.0 to 326.6) |
Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.
| percent change | Apremilast 20 mg PO BID (Treatment Phase) |
|---|---|
| Percent Change From Baseline in the IL8 Inflammatory Marker in Psoriatic Skin Biopsies | -66.5 (-100.0 to 136.2) |
Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.
| percent change | Apremilast 20 mg PO BID (Treatment Phase) |
|---|---|
| Percent Change From Baseline in the MX1 (Gene That Encodes the Interferon-induced p78 Protein) Inflammatory Marker in Psoriatic Skin Biopsies | -52.6 (-97.0 to -1.3) |
Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.
| percent change | Apremilast 20 mg PO BID (Treatment Phase) |
|---|---|
| Percent Change From Baseline in the IL17A Inflammatory Marker in Psoriatic Skin Biopsies | -49.4 (-100.0 to 76.8) |
Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.
| percent change | Apremilast 20 mg PO BID (Treatment Phase) |
|---|---|
| Percent Change From Baseline in the Tumor Necrosing Factor (TNF) Alpha Inflammatory Marker in Psoriatic Skin Biopsies | -42.7 (-100.0 to 242.9) |
Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.
| percent change | Apremilast 20 mg PO BID (Treatment Phase) |
|---|---|
| Percent Change From Baseline in the Interferon (INF) Gamma Inflammatory Marker in Psoriatic Skin Biopsies | -37.6 (-100.0 to 250.3) |
Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.
| percent change | Apremilast 20 mg PO BID (Treatment Phase) |
|---|---|
| Percent Change From Baseline in the IL10 Inflammatory Marker in Psoriatic Skin Biopsies | -26.5 (-100.0 to 565.0) |
Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.
| percent change | Apremilast 20 mg PO BID (Treatment Phase) |
|---|---|
| Percent Change From Baseline in the Chemokine Ligand (CXCL9) Inflammatory Marker in Psoriatic Skin Biopsies | -36.4 (-97.1 to 1021.2) |
Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.
| percent change | Apremilast 20 mg PO BID (Treatment Phase) |
|---|---|
| Percent Change From Baseline in the IL2 Inflammatory Marker in Psoriatic Skin Biopsies | -25.0 (-100.0 to 875.7) |
Inflammatory markers associated with psoriasis (using skin biopsies) were used to detect acute inflammation and as markers of treatment response. The inflammatory markers were measured using Reverse transcriptase polymerase chain reaction (RT-PCR) and the messenger Ribonucleic acid (mRNA) is being measured.
| percent change | Apremilast 20 mg PO BID (Treatment Phase) |
|---|---|
| Percent Change From Baseline in the Dendritic Cell (CD83) Inflammatory Marker in Psoriatic Skin Biopsies | 14.2 (-98.5 to 162.1) |
DLQI was the dermatology-specific quality of life (QOL) measure used for the psoriatic population. The DLQI was a validated, self-administered, 10-item questionnaire that measures the impact of skin disease on a participants QoL, based on recall over the past week. Domains include symptoms, feelings, daily activities, leisure, work, personal relationships, and treatment. Possible responses for each of the 10 items are: not at all, a little, a lot, and very much. Each question is rated on a scale of 0 to 3 with a total range of 0 to 30. Higher scores indicate greater impact of disease on QOL
| units on a scale | Apremilast 20 mg PO BID (Treatment Phase) |
|---|---|
| Change From Baseline in the Dermatology Life Quality Index (DLQI) at Week 12 | -4.7 ± 8.66 |
The SF-36 was a self-administered instrument consisting of 8 multi-item scales that assess 8 health domains: 1) limitations in physical activities because of health problems; 2) limitations in social activities because of physical or emotional problems; 3) limitations in usual role activities because of physical health problems; 4) bodily pain; 5) general mental health (psychological distress and well-being); 6) limitations in usual role activities because of emotional problems; 7) vitality (energy and fatigue); and 8) general health perceptions. A higher score post-baseline is indicative of improvement in the disease state. The summary physical health score included physical functioning, role-physical, bodily pain and general health. The summary mental health score included: vitality, social functioning, role-emotional and mental health. The resulting score for each subscale is then standardized, to obtain values ranging from 0 to 100, with higher values indicating a better QOL.
| units on a scale | Apremilast 20 mg |
|---|---|
| Mental Component | 0.8 ± 7.45 |
| Physical Component | 2.4 ± 7.64 |
Plasma concentrations of apremilast were determined using validated chiral liquid chromatography-mass spectrometry methods (LC-MS/MS).
| ng*hr/mL | Apremilast 20/30mg BID |
|---|---|
| Area Under the Plasma Concentration Time-curve From 0 to 12 Hours Post Dose (AUC 0-12) During the Extension Phase | 2019.71 ± 63.62 |
The maximum observed plasma concentration of CC-10004 (Cmax); the maximum plasma concentration (Cmax) was obtained directly from the observed concentration-time data on Days 169/170.
| ng/mL | Apremilast 20mg/30mg PO BID (Treatment + Extension Phase) |
|---|---|
| Peak (Maximum) Plasma Concentration of Apremilast (Cmax) During the Extension Phase | 320.35 ± 47.64 |
The time to reach Cmax (Tmax) was obtained directly from the observed concentration-time data on Day 169/170. Actual times utilized were used for reporting Tmax values.
| hours | Apremilast 20mg BID/30mg PO BID (Treatment + Extension Phase) |
|---|---|
| Time to Maximum Plasma Concentration (Tmax) During the Extension Phase | 1.59 ± 42 |
Terminal phase elimination half-life (t1/2) was calculated as follows: t1/2 = 0.693/λz. The terminal elimination rate constant (λZ) was estimated by linear regression of the log-transformed concentration-time data.
| hours | Apremilast 20mg/30mg PO BID (Treatment + Extension Phase) |
|---|---|
| Terminal Phase Elimination Half Life of Apremilast (t½) During the Extension Phase | 6.287 ± 22.879 |
For 169/170, apparent clearance of drug from plasma after extravascular administration (CL/F) was calculated as follows: CL/F= Dose/AUC12
| mL/hour | Apremilast 20mg/30mg PO BID (Treatment + Extension Phase) |
|---|---|
| Apparent Total Clearance of Apremilast From Plasma After Extravascular Administration (CL/F) During the Extension Phase | 14853.59 ± 63.62 |
For Days 169/170, apparent volume of distribution of drug (V/z) based on the terminal phase was calculated as follows: Vz/F=Dose/(λ\*AUC12) where λ = the terminal elimination rate constant
| mL | Apremilast 20mg BID/30mg PO BID (Treatment + Extension Phase) |
|---|---|
| Apparent Total Volume of Distribution During the Terminal Phase After Extravascular Administration (Vz/F) During the Extension Phase | 134734.60 ± 63.70 |
Accumulation represents the relationship between the dosing interval and the rate of elimination for the drug.
No measurements were reported for this outcome.
Mean Residence Time (MRT) is defined as the mean duration of time the drug spends in the body. The average concentration at steady state (Cavg) (for Days169/170) was calculated as follows: Cavg = (Day 169/170)/(12)
| hours | Apremilast 20mg/30mg PO BID (Treatment + Extension Phase) |
|---|---|
| Mean Residence Time (MRT) During the Extension Phase | 168.3092 ± 63.6203 |
Collected over Days 1 to Day 196 visit; Adverse Events (AE) were reported from the first day of study drug treatment through the 28 day observational follow up period. Maximum exposure to study medication was 171 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Apremilast 20 mg (Treatment Phase) | — | 0/30 (0%) | 25/30 (83.3%) |
| Apremilast 20mg/20mg (Extension Phase) | — | 0/4 (0%) | 4/4 (100%) |
| Apremilast 20mg/30mg (Extension Phase) | — | 1/7 (14.3%) | 4/7 (57.1%) |
| Event | Apremilast 20 mg (Treatment Phase) | Apremilast 20mg/20mg (Extension Phase) | Apremilast 20mg/30mg (Extension Phase) |
|---|---|---|---|
| ARRHYTHMIACardiac disorders | 0/30 | 0/4 | 1/7 |
| HYPERTENSIVE HEART DISEASECardiac disorders | 0/30 | 0/4 | 1/7 |
| MYOCARDIAL INFARCTIONCardiac disorders | 0/30 | 0/4 | 1/7 |
| Event | Apremilast 20 mg (Treatment Phase) | Apremilast 20mg/20mg (Extension Phase) | Apremilast 20mg/30mg (Extension Phase) |
|---|---|---|---|
| PAIN IN EXTREMITYMusculoskeletal and connective tissue disorders | 0/30 | 0/4 | 2/7 |
| EPISTAXISRespiratory, thoracic and mediastinal disorders | 1/30 | 0/4 | 2/7 |
| NASOPHARYNGITISInfections and infestations | 1/30 | 1/4 | 1/7 |
| LOWER RESPIRATORY TRACT INFECTIONInfections and infestations | 1/30 | 1/4 | 0/7 |
| NECK PAINMusculoskeletal and connective tissue disorders | 0/30 | 1/4 | 0/7 |
| OSTEOARTHRITISMusculoskeletal and connective tissue disorders | 0/30 | 1/4 | 0/7 |
| INFLUENZA LIKE ILLNESSGeneral disorders | 1/30 | 1/4 | 0/7 |
| OEDEMA PERIPHERALGeneral disorders | 0/30 | 1/4 | 0/7 |
| PRODUCTIVE COUGHRespiratory, thoracic and mediastinal disorders | 1/30 | 1/4 | 0/7 |
| CORNEAL ABRASIONInjury, poisoning and procedural complications | 0/30 | 1/4 | 0/7 |
Safety population consisted of all participants who were enrolled and received at least one dose of study medication.
| Age, Continuous(years) | Apremilast 20 mg (Treatment Phase) |
|---|---|
| Mean | 46.3 ± 11.43 |
| Sex: Female, Male(Participants) | Apremilast 20 mg (Treatment Phase) |
|---|---|
| Female | 11 |
| Male | 19 |
| Recalcitrant Psoriasis History(years) | Apremilast 20 mg (Treatment Phase) |
|---|---|
| Mean | 10.9 ± 11.36 |
| Mean Psoriasis Area and Severity Index (PASI) Score(units on a scale) | Apremilast 20 mg (Treatment Phase) |
|---|---|
| Mean | 17.0 ± 6.77 |
| Mean Body Surface Area (BSA) Involvement(Percentage of BSA) | Apremilast 20 mg (Treatment Phase) |
|---|---|
| Mean | 22.4 ± 13.85 |
Ran from Aug 2007 to primary completion in Apr 2009, 20 months.
Results were first posted in Oct 2014, 5 years 6 months after primary completion. A results delay was requested in Aug 2010.
Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 20 months is above that.
Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apremilast